Previous Article | Next Article ![]()
Journal of Clinical Microbiology, June 2000, p. 2215-2218, Vol. 38, No. 6
Department of General
Pharmacology,1 Institute for Laboratory
Animal Science,2 and Department of
Gastroenterology and Hepatology,3 Medizinische
Hochschule Hannover, D-30625 Hannover, Germany
Received 23 August 1999/Returned for modification 15 December
1999/Accepted 27 March 2000
The aim of this study was to investigate the effect of
Helicobacter pylori on the function of gastric mucous
cells. H. pylori (104 to 107
CFU/well) was incubated with the mucin-producing gastric cell line HM02
for 12 and 24 h. Mucin synthesis and secretion were determined by
the incorporation of
D-N-[acetyl-14C]glucosamine
into intracellular and released high-molecular-weight glycoproteins.
cagA-positive, cytotoxin-producing and
non-cytotoxin-producing H. pylori strains impaired the
incorporation of
D-N-[acetyl-14C]glucosamine
into intracellular glycoproteins. Significant inhibition of mucin
synthesis was noted after 12 and 24 h of cocultivation with a
bacterial load of
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Role of vacA and cagA in
Helicobacter pylori Inhibition of Mucin Synthesis in Gastric
Mucous Cells
105 bacteria (bacterium/cell ratio = 0.25). The cagA-positive, cytotoxin-producing strains
(HP64, HP57, and HP87) caused significantly stronger inhibition of
intracellular mucin synthesis than the cagA-positive,
non-cytotoxin-producing strains (HP05, HP83, and HP84). The
cagA-negative, non-cytotoxin-producing strains (HP01, HP04,
and HP85) did not affect intracellular mucin synthesis. The results
indicate that H. pylori directly impairs mucin synthesis in
gastric mucous cells and that cytotoxic cagA-positive strains cause more profound inhibition of mucin synthesis. We suggest
that the increased inhibitory effect of cagA-positive, cytotoxin-producing strains on mucin synthesis can be considered one
possible factor responsible for the increased risk of developing peptic
ulceration with these H. pylori strains.
*
Corresponding author. Mailing address: Institut
für Pharmakologie, Medizinische Hochschule Hannover,
Carl-Neuberg-Str. 1, D-30625 Hannover, Germany. Phone:
49/511-5322951. Fax: 49/511-5322794. E-mail:
stanke.annette{at}mh-hannover.de.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|